Laura W. Goff, MD

Dr. Laura Goff presents treatment updates in hepatocellular carcinoma (HCC) that were presented at the ASCO 2021 Annual Meeting.

Updated data from the phase 3 KEYNOTE-240 study demonstrated that overall survival, progression-free survival, and objective response rate were maintained over 3 years with pembrolizumab compared to placebo in patients with advanced HCC previously treated with sorafenib.

An exploratory analysis of IMBRAVE150 examined the association between best overall response and overall survival, as well as independent predictors of survival in patients with unresectable HCC treated with atezolizumab plus bevacizumab versus sorafenib. In the study treatment population, confirmed response by RECIST 1.1 and by HCC mRECIST were associated with improved overall survival. Data suggested that both confirmed response and stable disease are associated with improved clinical outcomes in patients treated with this regimen.

Lastly, a retrospective cohort study comparing sorafenib, and nivolumab as first-line systemic therapies for patients with advanced HCC and Child-Pugh class B cirrhosis found that nivolumab was associated with better overall survival as a first-line treatment.

--

Laura W. Goff, MD is an Associate Professor at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Goff discloses previous work with: Agios, ArQule; ASLAN Pharmaceuticals; Astellas Pharma; Basilea Pharmaceutica; BeiGene; Bristol Myers Squibb; Eli Lilly and Company; H3 Biomedicine; Incyte; Leap Therapeutics; Merck; Onyx Pharmaceuticals; Pfizer; SunPharma.

Dr. Laura Goff presents treatment updates in hepatocellular carcinoma (HCC) that were presented at the ASCO 2021 Annual Meeting.

Updated data from the phase 3 KEYNOTE-240 study demonstrated that overall survival, progression-free survival, and objective response rate were maintained over 3 years with pembrolizumab compared to placebo in patients with advanced HCC previously treated with sorafenib.

An exploratory analysis of IMBRAVE150 examined the association between best overall response and overall survival, as well as independent predictors of survival in patients with unresectable HCC treated with atezolizumab plus bevacizumab versus sorafenib. In the study treatment population, confirmed response by RECIST 1.1 and by HCC mRECIST were associated with improved overall survival. Data suggested that both confirmed response and stable disease are associated with improved clinical outcomes in patients treated with this regimen.

Lastly, a retrospective cohort study comparing sorafenib, and nivolumab as first-line systemic therapies for patients with advanced HCC and Child-Pugh class B cirrhosis found that nivolumab was associated with better overall survival as a first-line treatment.

--

Laura W. Goff, MD is an Associate Professor at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Goff discloses previous work with: Agios, ArQule; ASLAN Pharmaceuticals; Astellas Pharma; Basilea Pharmaceutica; BeiGene; Bristol Myers Squibb; Eli Lilly and Company; H3 Biomedicine; Incyte; Leap Therapeutics; Merck; Onyx Pharmaceuticals; Pfizer; SunPharma.

Dr. Laura Goff presents treatment updates in hepatocellular carcinoma (HCC) that were presented at the ASCO 2021 Annual Meeting.

Updated data from the phase 3 KEYNOTE-240 study demonstrated that overall survival, progression-free survival, and objective response rate were maintained over 3 years with pembrolizumab compared to placebo in patients with advanced HCC previously treated with sorafenib.

An exploratory analysis of IMBRAVE150 examined the association between best overall response and overall survival, as well as independent predictors of survival in patients with unresectable HCC treated with atezolizumab plus bevacizumab versus sorafenib. In the study treatment population, confirmed response by RECIST 1.1 and by HCC mRECIST were associated with improved overall survival. Data suggested that both confirmed response and stable disease are associated with improved clinical outcomes in patients treated with this regimen.

Lastly, a retrospective cohort study comparing sorafenib, and nivolumab as first-line systemic therapies for patients with advanced HCC and Child-Pugh class B cirrhosis found that nivolumab was associated with better overall survival as a first-line treatment.

--

Laura W. Goff, MD is an Associate Professor at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Goff discloses previous work with: Agios, ArQule; ASLAN Pharmaceuticals; Astellas Pharma; Basilea Pharmaceutica; BeiGene; Bristol Myers Squibb; Eli Lilly and Company; H3 Biomedicine; Incyte; Leap Therapeutics; Merck; Onyx Pharmaceuticals; Pfizer; SunPharma.